Showing results (91-100 of 117) with videos related to
Sort By:
Pageof 12
Journal of the American Academy of Dermatology|November 17, 2025
Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extensionChristopher J Sayed, Brian Kirby, Amit Garg, et al.Pain and Therapy|October 17, 2025
Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical TrialsJohn R Ingram, Hideki Fujita, Alice B Gottlieb, et al.EMBO Reports|November 12, 2020
Chemical targeting of NEET proteins reveals their function in mitochondrial morphodynamicsDiana Molino, Irene Pila-Castellanos, Henri-Baptiste Marjault, et al.The Journal of Allergy and Clinical Immunology|May 14, 2022
Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosisDaniel McCluskey, Natashia Benzian-Olsson, Satveer K Mahil, et al.Lancet (London, England)|May 25, 2024
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trialsAlexa B Kimball, Gregor B E Jemec, Christopher J Sayed, et al.The British Journal of Dermatology|November 17, 2023
Global consensus process to establish a core dataset for hidradenitis suppurativa registriesHannah E Wainman, Nisha S Chandran, John W Frew, et al.Journal of the American Academy of Dermatology|March 18, 2019
Navigating the landscape of core outcome set development in dermatologyCecilia A C Prinsen, Phyllis I Spuls, Jan Kottner, et al.Skin Health and Disease|August 1, 2026
Healthcare resource use, costs and health-related quality of life in the UK-Irish Atopic eczema Systemic Therapy Register (A-STAR): a pilot studyCarlos Chivardi, Elizaveta Gribaleva, Bolaji Coker, et al.Dermatology (Basel, Switzerland)|February 14, 2024
The Global Hidradenitis Suppurativa Atlas Methodology: Combining Global Proportions in a Pooled AnalysisDorra Bouazzi, Rune K Andersen, Gabrielle R Vinding, et al.JAAD International|November 17, 2022
Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin typesAngela L Bosma, Wouter Ouwerkerk, Madeline J Heidema, et al.Pageof 12